Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

21 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Characterizing the real-world economic burden of metastatic castration-sensitive prostate cancer in the United States.
Kaye DR, Khilfeh I, Muser E, Morrison L, Kinkead F, Lefebvre P, Pilon D, George D. Kaye DR, et al. Among authors: khilfeh i. J Med Econ. 2024 Jan-Dec;27(1):381-391. doi: 10.1080/13696998.2024.2323901. Epub 2024 Mar 11. J Med Econ. 2024. Update in: J Med Econ. 2024 Jan-Dec;27(1):605. doi: 10.1080/13696998.2024.2340918 PMID: 38420699 Free article. Updated.
Real-world economic burden of metastatic castration-resistant prostate cancer before and after first-line therapy initiation.
Kaye DR, Khilfeh I, Muser E, Morrison L, Kinkead F, Urosevic A, Lefebvre P, Pilon D, George DJ. Kaye DR, et al. Among authors: khilfeh i. J Med Econ. 2024 Jan-Dec;27(1):201-214. doi: 10.1080/13696998.2024.2303890. Epub 2024 Feb 2. J Med Econ. 2024. Update in: J Med Econ. 2024 Jan-Dec;27(1):518. doi: 10.1080/13696998.2024.2336778 PMID: 38204397 Free article. Updated.
Comparison of prostate-specific antigen response in patients with metastatic castration-sensitive prostate cancer initiated on apalutamide or abiraterone acetate: A retrospective cohort study.
Lowentritt B, Pilon D, Waters D, Rossi C, Muser E, Kurteva S, Shah A, Khilfeh I, Du S, Ellis L, Lefebvre P, Brown G. Lowentritt B, et al. Among authors: khilfeh i. Urol Oncol. 2023 May;41(5):252.e19-252.e27. doi: 10.1016/j.urolonc.2023.03.013. Epub 2023 Apr 19. Urol Oncol. 2023. PMID: 37080833 Free article.
Attainment of early, deep prostate-specific antigen response in metastatic castration-sensitive prostate cancer: A comparison of patients initiated on apalutamide or enzalutamide.
Lowentritt B, Pilon D, Khilfeh I, Rossi C, Muser E, Kinkead F, Waters D, Ellis L, Lefebvre P, Brown G. Lowentritt B, et al. Among authors: khilfeh i. Urol Oncol. 2023 May;41(5):253.e1-253.e9. doi: 10.1016/j.urolonc.2023.03.003. Epub 2023 Apr 13. Urol Oncol. 2023. PMID: 37061452 Free article.
21 results